At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Dose adjust group (NFAT)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients
In Brief
A clinical study evaluating Dose adjust group (NFAT) for Kidney Transplantation. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to compare two different ways of monitoring the immune system to determine how to manage the doses of anti-rejection medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesUnited States
CollaboratorsAstellas Pharma Inc
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartMay 2013
Primary CompletionAug 2016
Study CompletionApr 2017
TodayJul 2026
First PostedJan 18, 2013
Enrollment StartMay 2, 2013
Primary CompletionAug 13, 2016
Study CompletionApr 17, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.5 years ago
Interventions
Dose adjust group (NFAT)other
If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.